Panelists discuss how specific biomarkers, such as GPRC5D expression levels, and clinical features, influence their decision to initiate GPRC5D bispecific therapies in multiple myeloma patients.
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.